This study is looking at a new imaging agent called 99mTc-ECDG to see how well it can detect coronary artery disease (CAD), a condition where the heart's arteries narrow. Researchers will compare 99mTc-ECDG to a standard test called 99mTc-Sestamibi during rest and stress heart scans. The goal is to see if 99mTc-ECDG is effective and safe in finding the presence, location, and seriousness of CAD, as confirmed by a coronary angiogram (a procedure to look at your heart's blood vessels). About 60 adults aged 18 and older who have been evaluated for CAD and are planning or have recently had a coronary angiogram may be able to join. The study will measure how well 99mTc-ECDG works over approximately 3 to 20 days.

Study design

This is an open-label (meaning you and your doctors will know which treatment you are receiving), multi-center study involving about 60 participants.

What's involved

You would undergo a sequence of imaging procedures, including 99mTc-EC-DG rest and stress studies, and a 99mTc-SPECT MPI rest/stress study, over a period of approximately 3 to 20 days.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for efficacy is measured from Visit 1a through Visit 3, which is approximately 3 to 20 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.